ASBMR 2014: Four bone drug updates, including Merck's odanacatib

Merck & Co reported positive Phase III efficacy for its osteoporosis drug odanacatib during the American Society for the Bone and Mineral Research (ASBMR) Annual Meeting from 12 to 15 September in Houston, Texas, but the company will not seek US FDA approval until 2015.